Clinical research and scientific evidence confirm the role of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] as a risk factor for atherosclerosis and cardiovascular events. To date there still remains a group of patients who, despite the new lipid-lowering drugs, do not reach LDL-cholesterol and/or Lp(a) target indicated by the guidelines [1]. In these patients the lipoprotein apheresis (LA) treatment, in use for more than 45 years, is the most effective means to lowering the apo-B containing atherogenic lipoproteins [2].
